Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Recommendation of "Moderate Buy" from Brokerages

robot
Abstract generation in progress

Summit Therapeutics PLC (NASDAQ:SMMT) has received an average “Moderate Buy” rating from sixteen brokerages, with an average one-year price target of $32.25. The company’s stock is currently trading around $14.94, and it reported a quarterly EPS loss of $0.29, missing analyst expectations. Institutional investors, including Vanguard Group Inc. and Norges Bank, have recently increased their holdings in SMMT.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin